Loading organizations...
Founded in 2018 by Vishal Doshi and co-founder Harish Dave, AUM Biosciences is a Singapore-based clinical-stage biotechnology company that discovers and develops precision oncology therapeutics designed to successfully reverse cancer resistance. The enterprise advances a robust clinical pipeline of targeted medicines utilizing multi-faceted inhibition strategies to address high unmet medical needs in oncology patients. The pharmaceutical developer secured a $27 million Series A funding round in October 2021 backed by institutional investors including Everlife and SPRIM Global Investments. In October 2022, the organization reached an estimated valuation of approximately $400 million during a proposed public listing via a special purpose acquisition company merger with Mountain Crest Acquisition Corp V. The two entities mutually terminated this merger agreement in June 2023, keeping the biotechnology firm private as it continues its ongoing clinical research and development operations.
AUM Biosciences has raised $27.0M across 1 funding round.
AUM Biosciences has raised $27.0M in total across 1 funding round.
AUM Biosciences has raised $27.0M in total across 1 funding round.
AUM Biosciences's investors include Arjun Oberoi, SPRIM Global Investments.
AUM Biosciences has raised $27.0M across 1 funding round. Most recently, it raised $27.0M Series A in October 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 13, 2021 | $27M Series A | Arjun Oberoi | Sprim Global Investments | Announced |
